What is the recommended frequency of the Respiratory Syncytial Virus (RSV) vaccine administration?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 4, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

RSV Vaccine Frequency

The RSV vaccine for adults is administered as a single lifetime dose, not requiring annual or repeated vaccination. 1

Adult Vaccination Schedule

A single dose of RSV vaccine is currently recommended for eligible adults, with no booster doses required. 1 This represents a fundamental difference from annual influenza vaccination and reflects the sustained immune response generated by current RSV vaccines.

Optimal Timing of Administration

  • The vaccine should preferably be administered between September and November, before or early in the RSV season, to maximize protection during peak transmission months. 2, 1
  • While vaccination can occur at any time of year, pre-season administration ensures optimal antibody levels when exposure risk is highest. 2, 3
  • In the Northern Hemisphere, RSV season typically runs from November through April, though timing may vary by geographic region. 1

Duration of Protection

The available evidence demonstrates sustained vaccine efficacy over multiple RSV seasons:

  • RSVPreF3 (Arexvy) maintains efficacy for at least three seasons in adults aged ≥60 years. 2, 3
  • RSVpreF (Abrysvo) maintains efficacy for at least two seasons in adults aged ≥60 years. 2, 3

These data support the current single-dose recommendation, though longer-term surveillance continues to evaluate whether future booster doses may eventually be needed. 4

Pediatric RSV Prevention: Different Approach

Pediatric RSV prevention uses a fundamentally different strategy than adult vaccination, relying on either maternal vaccination or monoclonal antibody administration rather than direct infant vaccination:

Maternal Vaccination

  • Pregnant individuals receive a single dose of RSVpreF between weeks 28-36 of gestation (optimally 32-36 weeks) to protect infants from birth through 6 months of age. 1, 3
  • This is administered seasonally (September through January in most continental US regions). 3
  • There is currently no RSV vaccine approved for direct administration to neonates or infants. 5

Monoclonal Antibody (Palivizumab/Synagis)

  • High-risk infants receive monthly intramuscular injections throughout the RSV season, administered every 28-30 days. 6
  • This requires 5 monthly doses during a typical RSV season for continuous protection. 6
  • Each injection provides approximately 1 month of protection, necessitating the monthly dosing schedule. 6

Important Clinical Considerations

Co-administration with Other Vaccines

  • RSV vaccine can be co-administered with seasonal influenza vaccine at different injection sites. 2, 1, 3
  • Some studies show numerically lower antibody titers for both RSV and influenza when co-administered, though clinical significance remains unknown. 2
  • Data on co-administration with COVID-19 vaccines are lacking. 2

Common Pitfalls to Avoid

  • Do not confuse the single-dose adult vaccine schedule with the monthly pediatric monoclonal antibody regimen - these are entirely different products with different dosing requirements. 1, 6
  • Previous RSV infection does not confer long-lasting immunity and does not contraindicate vaccination - patients should still receive the vaccine even with prior RSV disease. 1
  • Do not delay vaccination waiting for "perfect" timing - if RSV season has already begun, administer as soon as possible rather than waiting until the following year. 6

Declining Efficacy Considerations

While vaccine efficacy decreases over time (as expected for a virus characterized by short-term natural immunity), efficacy remains clinically meaningful over placebo through at least 2-3 seasons. 4 Current guidelines do not recommend booster doses, but ongoing surveillance may inform future recommendations as longer-term data accumulate. 4

References

Guideline

RSV Vaccination Recommendations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

RSV Vaccine Recommendations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

RSV: an update on prevention and management.

Australian prescriber, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.